Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VPM1002 for Prevention of TB Recurrence
NCT03152903Phase 3Completed
- Sponsor
- Serum Institute of India
- Start
- Dec 2017
- Primary completion
- Dec 2023
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Tuberculosis (TB) comparing VPM1002 with Placebo (2 arms). Primary endpoint: Percentage of bacteriologically confirmed TB recurrence cases. Started Dec 2017; status: completed.
02
Drugs
VPM1002
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03152903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03152903.